Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005;19(3):225-38.
doi: 10.2165/00023210-200519030-00004.

Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?

Affiliations
Review

Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?

Tong J Gan. CNS Drugs. 2005.

Abstract

Selective serotonin 5-HT(3) receptor antagonists have proven safe and effective for the management of postoperative nausea and vomiting. Dolasetron, granisetron, ondansetron and tropisetron selectively and competitively bind to 5-HT(3) receptors, blocking serotonin binding at vagal afferents in the gut and in the regions of the CNS involved in emesis, including the chemoreceptor trigger zone and the nucleus tractus solitarii. Despite their shared mechanism of action, 5-HT(3) receptor antagonists have different chemical structures and exhibit differences in receptor binding affinity, dose response and duration of effect. Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents. Hence, although these agents are considered equally effective in the overall population, their pharmacokinetic and pharmacodynamic differences may explain the variability in individual responses to these drugs. This review discusses the pharmacological profiles of dolasetron, granisetron, ondansetron and tropisetron, and the clinical implications of differences in their profiles.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Anesth Analg. 2002 Jun;94(6):1553-7, table of contents - PubMed
    1. Am J Health Syst Pharm. 1997 May 15;54(10):1172-6 - PubMed
    1. Eur J Clin Pharmacol. 1999 May;55(3):177-84 - PubMed
    1. Anesthesiology. 1996 Nov;85(5):1076-85 - PubMed
    1. J Cardiovasc Pharmacol. 1996 Jul;28(1):53-9 - PubMed

MeSH terms

LinkOut - more resources